在老鼠中氧化的药理动力学:微化酸乳酸对氧化生物可用性的影响
Daniel Ortega Hijano1, Sylwia Flis2, Karol Ofiara1
1ASLAB Science, Fort Służew 1/9, 02-787, Warsaw, Poland.
European journal of pharmacology
|March 27, 2025
概括
研究了酸乳酸对氧化化生物可用性的影响. 研究人员发现,离子 (Mg2+) 降低了氧化的吸收,这与之前关于阿片类药物增强作用的假设相反.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物开发 药物开发
- 分析化学 分析化学
背景情况:
- 氧化二化是一种广泛使用的阿片类止痛药.
- (Mg2+) 已被研究了与阿片类药物的潜在协同作用,以增强镇痛和降低剂量.
- 和氧化之间的药理学相互作用尚未完全阐明.
研究的目的:
- 为了研究微化乳酸对氧化酸的生物可用性和药理动学的影响.
- 开发和验证用于量化氧化和其代谢物氧化的分析方法.
- 评估一种新型配方的潜力,该配方将氧化化与Mg2+结合起来,以改善疼痛缓解.
主要方法:
- 开发和验证高性能液体染色学与二极管阵列检测 (HPLC-DAD) 和高性能液体染色学与并联质谱法 (HPLC-MS/MS) 的方法.
- 用同位素稀释在药物配方中的氧科化和大鼠血清中的氧摩的量化.
- 在Wistar大鼠中进行的药理动力学研究,涉及到含有或不含微化乳酸的氧化化配方的胃内给药.
主要成果:
- 发现Mg2+的存在降低了氧化二的生物可用性.
- 观察到的相互作用归因于离子和配方成分之间的化学反应.
- 在研究Mg2+和阿片类药物相互作用的研究中,以前没有考虑这种对生物可用性的影响.
结论:
- 微化乳酸盐对氧化二的生物可用性产生负面影响.
- 和氧化配方之间的化学相互作用是导致吸收减少的原因.
- 以前关于在增强阿片类药物效应中的作用的研究可能需要重新评估,因为这种被忽视的药理动力学相互作用.
相关概念视频
01:16Bioavailability Enhancement: Drug Solubility Enhancement
Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
01:20Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
01:30Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...